PPIDT00062
Drug Information
| Name | Rituximab |
|---|---|
| Sequence | QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB00073 |
| Type | biotech |
| Indication | Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.[L26641,L42025,L42030,L42035,L42040] Additionally, rituximab is indicated for the treatment of adult patients with non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy; and previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.[L26641,L42025,L42030,L42035,L42040] Rituximab, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).[L26641,L42025,L42030,L42035,L42040] In combination with methotrexate, rituximab is indicated for the treatment of adult patients with moderately-to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.[L26641,L42025,L42030,L42035] Additionally, rituximab, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA).[L26641,L42025,L42030,L42035] RITUXAN (rituximab injection for intravenous use) is indicated for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy; as well as the treatment of adult patients with moderate to severe pemphigus vulgaris.[L26641] These indications for RITUXAN are not included in the labels of rituximab biosimilar products (rituximab-arrx, rituximab-abbs, rituximab-pvvr).[L42025,L42030,L42035] The combination product RITUXAN HYCELA (rituximab and hyaluronidase human injection, for subcutaneous use) is not indicated for the treatment of non-malignant conditions.[L42040] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Solution | Intravenous |
100.0 mg
|
| Solution | Intravenous; Subcutaneous |
1000000 mg
|
| Solution | Parenteral |
100 mg
|
| Solution, concentrate | Intravenous |
50000000 mg
|
| Solution | Intravenous |
10000000 mg
|
| Injection | Intravenous |
1400 MG/11.7ML
|
| Injection, solution | Subcutaneous |
1600 mg
|
| Injection, solution, concentrate | Intravenous |
10 mg/1ml
|
| Injection, solution, concentrate | Intravenous |
100 mg
|
| Injection, solution, concentrate | Intravenous |
500 mg
|
| Solution | — |
10 mg/1ml
|
| Solution | Intravenous |
100.000 mg
|
| Solution | Intravenous |
500 mg
|
| Solution | Intravenous |
50000000 mg
|
| Injection | Intravenous |
100 mg/10ml
|
| Injection, solution, concentrate | Intravenous |
100 MG/10ML
|
| Injection, solution | Intravenous |
120 mg/mL
|
| Injection | Intravenous |
500 mg/50ml
|
| Injection, solution, concentrate | Intravenous |
500 MG/50ML
|
| Solution | Intravenous |
10 mg/ml
|
| Injection | Intravenous |
10 mg/ml
|
| Solution | Intravenous |
10 mg
|
| Solution | Intravenous |
1000000 mg
|
| Injection, solution | Subcutaneous |
1400 mg
|
| Solution, concentrate | Intravenous |
10 mg/ml
|
| Solution | Subcutaneous |
120 mg
|
| Solution | Subcutaneous |
12000000 mg
|
| Injection; injection, solution, concentrate | Intravenous |
10 MG/ML
|
| Solution | Intravenous |
500.000 mg
|
| Injection, solution | Intravenous |
10 mg/1mL
|
| Solution | Intravenous |
10 mg / mL
|
| Injection, solution | Subcutaneous |
|
| Solution | Subcutaneous |
1400 mg / 11.7 mL
|
| Solution | Subcutaneous |
1600 mg / 13.4 mL
|
| Injection, solution, concentrate | — |
100 mg/10ml
|
| Injection, solution, concentrate | — |
500 mg/50ml
|
| Solution | Intravenous |
100 mg/10ml
|
| Solution | Intravenous |
500 mg/50ml
|
| Solution, concentrate | Intravenous |
1000000 mg
|
| Injection, solution | Intravenous |
100 mg/10mL
|
| Injection, solution | Intravenous |
500 mg/50mL
|
| Injection, solution, concentrate | Intravenous; Parenteral |
100 MG
|
| Solution, concentrate | Intravenous |
10 mg
|
| Injection, solution, concentrate | Intravenous; Parenteral |
500 MG
|
| Solution | Intravenous |
100 mg / 10 mL
|
| Solution | Intravenous |
500 mg / 50 mL
|
| — | — |
10 mg/1ml
|
| Injection, solution | — |
1400 mg/11.7ml
|